Welcome to issue 39 of Multiple Myeloma Research Review. This issue’s selection includes research reporting that switching elderly intermediate-fit patients with MM to reduced-dose lenalidomide maintenance without dexamethasone after nine cycles of Rd was both feasible and provided outcomes similar to those associated with continuing Rd. As usual we have attached the PDF, and now...Continue Reading
Welcome to issue 37 of Multiple Myeloma Research Review. This issue begins with a retrospective, multinational report describing the clinical features associated with outcomes of patients with MM who had acquired SARS-COV-2 infection. There is also research demonstrating that autologous HSCT is an important therapy among patients with MM, even our elderly patients. Researchers from...Continue Reading
Welcome to issue 36 of Multiple Myeloma Research Review. The use of ixazomib-based induction therapy in routine clinical practice is relatively uncommon for several reasons, so the first study for this issue is useful, as it describes the effectiveness and safety of such treatment in a multicentre cohort of real-world patients. US research has confirmed...Continue Reading
Highlights include: Associations with OS in NZ MM patients VTE risk with lenalidomide regimens for MM despite thromboprophylaxis Retrospective study of with t(14;16) MM Download here: Multiple Myeloma Research Review Issue 34Continue Reading
Highlights include: Daratumumab + standard care in newly diagnosed MM OS with daratumumab + bortezomib/melphalan/prednisone in newly diagnosed MM Frontline treatment of elderly non transplant-eligible MM patients using cyclophosphamide, bortezomib, dexamethasone Download here: Multiple Myeloma Research Review Issue 33Continue Reading
Highlights include: • Once-weekly vs twice weekly carfilzomib for newly diagnosed MM • Negative trials for pembrolizumab in treatment naive and relapsed/refractory MM • Daratumumab plus dexamethasone in triple refractory MM Download here: Multiple Myeloma Research Review Issue 32Continue Reading
The impact of age, ethnicity and socio-economic deprivation in the era of novel anti-myeloma agents is unclear. Using linked national data from New Zealand, we evaluated the incidence, prevalence and overall survival (OS) of individuals who were diagnosed with myeloma between 2004 and 2016. The crude incidence rate increased from 5.42 to 8.47/100 000 and...Continue Reading
